Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide
NN9388-7864
Phase 2 small_molecule active
Quick answer
Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide for Type 2 diabetes and painful diabetic peripheral neuropathy is a Phase 2 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Type 2 diabetes and painful diabetic peripheral neuropathy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active